PubMed Health⌕ Search

Biomedical subjects

L Hidalgo

Publications and source records attributed to L Hidalgo.

At least 55 records · Page 3Linked to original sources
PubMedDate not supplied

[Monotopic coralliform calculus and simultaneous contralateral lithiasis].

A study is made of 15 patients with monotopic coralliform stones, suffering from simultaneous, contralateral, renoureteral lithiasis. There are certain special features in these patients which we consider to be sufficient to distinguish them as a separate group amond cases of lithiasis in general and coralliform stones in particular. The high percentage of septic complications observed in these patients demand special treatment within the field of urinary lithiasis.

Adult↗
PubMedDate not supplied

[Sonographic study of hydronephrosis].

The authors present the experience acquired by the Urology Department of "La Paz" Hospital in the sonographic diagnosis of hydronephrosis over a period of one year. In 47 patients, the percentage of successful diagnoses reached 93.7%, including 32 cases with a silent kidney in the intravenous urography. They discuss the different sonographic patterns of hydronephrosis, in relation to its degree of evolutionary development and its differential diagnosis with other kidney disorders.

Female↗
PubMedDate not supplied

[Clinical aspects of renal adenocarcinoma].

We present for study a series of 80 patients suffering from renal adenocarcinoma, pointing out that the most frequent reason for consultation was hematuria, observed in 44 patients (57.5%) which constituted at the same time the predominating initial symptom. The period of time which elapsed between its presentation and the diagnosis ranged, in most cases, between 1 and 6 months. There were numerous paraneoplastic findings, of which hyper-alpha2-globulinemia 21/25 patients (60%) and high sedimentation speed 41/80 (51.2%) were important due to their frequency. Metastases were detected in 16 patients with the most frequent location being the bone system, 11 cases (55%). We point out the need for a good knowledge of the varied evolutionary behaviour of this kind of neoplasia and the numerous systemic repercussions, with a view to obtaining an earlier diagnosis in the absence of local symptoms, in order to improve the prognosis.

Adenocarcinoma↗
PubMedDate not supplied

Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.

BACKGROUND: Elevation in total and low-density lipoprotein cholesterol levels and a decrease in high-density lipoprotein cholesterol plasma concentrations are common in heart transplant recipients. The pathogenesis of this hyperlipemia after heart transplantation is complex. Currently available antilipemic agents are difficult to use because their adverse effects are potentiated by immunosuppressor treatment. The present investigation was carried out to test the safety and efficacy of lovastatin and bezafibrate in 18 patients with hyperlipemia after heart transplantation. METHODS: In this crossover study, after 3 months of dietary recommendations, the subjects were randomly assigned to an 8-week period of lovastatin treatment (10 mg/day) followed by an additional 8-week period of treatment with bezafibrate (400 mg/day) or vice versa. The two treatments were separated by an 8-week washout period. RESULTS: Both drugs reduced total and low-density lipoprotein cholesterol and apoprotein B concentrations. High-density lipoprotein cholesterol was only increased with bezafibrate. The total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratios were decreased under both treatments, but these changes were greater with bezafibrate. Apo AI levels increased with lovastatin. Bezafibrate produced a rise in high-density lipoprotein cholesterol and reduced total and very low-density lipoprotein triglycerides and very low-density lipoprotein cholesterol. Both drugs decreased intermediate density lipoprotein cholesterol and triglyceride levels, but the effect of bezafibrate on intermediate-density lipoprotein triglycerides was significantly greater. The two drugs were well tolerated and liver enzymes, creatine kinase, and renal function remained stable.

Adult↗